The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma
Open accessAbstract
IMPORTANCE: Although patients with resected pancreatic adenocarcinoma are at high risk for disease recurrence, few biomarkers are available to inform patient outcomes. OBJECTIVE: To evaluate the alterations of the 4 main driver genes in pancreatic adenocarcinoma and patient outcomes after cancer resection. DESIGN, SETTING, AND PARTICIPANTS: This study analyzed protein expression and DNA alterations for the KRAS, CDKN2A, SMAD4, and TP53 genes by immunohistochemistry and next-generation sequencing in formalin-fixed, paraffin-embedded tumors in 356 patients with resected pancreatic adenocarcinoma who were treated at the Dana-Farber/Brigham and Women's Cancer Center (October 26, 2002, to May 21, 2012), University of Rochester Medical Center (March 1, 2006, to November 1, 2013), or Stanford Cancer Institute (September 26, 1995, to May 22, 2013). Associations of driver gene alterations with disease-free survival (DFS) and overall survival (OS) were evaluated using Cox proportional hazards regression with estimation of hazard ratios (HRs) and 95% CIs and adjustment for age, sex, tumor characteristics, institution, and perioperative treatment. Data were collected September 9, 2012, to June 28, 2016, and analyzed December 17, 2016, to March 14, 2017. MAIN OUTCOMES AND MEASURES: The DFS and OS among patients with resected pancreatic adenocarcinoma. RESULTS: Of the 356 patients studied, 191 (53.7%) were men and 165 (46.3%) were women, with a median (interquartile range [IQR]) age of 67 (59.0-73.5) years. Patients with KRAS mutant tumors had worse DFS (median [IQR], 12.3 [6.7 -27.2] months) and OS (20.3 [11.3-38.3] months) compared with patients with KRAS wild-type tumors (DFS, 16.2 [8.9-30.5] months; OS, 38.6 [16.6-63.1] months) and had 5-year OS of 13.0% vs 30.2%. Particularly poor outcomes were identified in patients with KRAS G12D-mutant tumors, who had a median (IQR) OS of 15.3 (9.8-32.7) months. Patients whose tumors lacked CDKN2A expression had worse DFS (median, 11.5 [IQR, 6.2-24.5] months) and OS (19.7 [10.9-37.1] months) compared with patients who had intact CDKN2A (DFS, 14.8 [8.2-30.5] months; OS, 24.6 [14.1-44.6] months). The molecular status of SMAD4 was not associated with DFS or OS, whereas TP53 status was associated only with shorter DFS (HR, 1.33; 95% CI, 1.02-1.75; P = .04). Patients had worse DFS and OS if they had a greater number of altered driver genes. Compared with patients with 0 to 2 altered genes, those with 4 altered genes had worse DFS (HR, 1.79 [95% CI, 1.24-2.59; P = .002]) and OS (HR, 1.38 [95% CI, 0.98-1.94; P = .06]). Five-year OS was 18.4% for patients with 0 to 2 gene alterations, 14.1% for those with 3 alterations, and 8.2% for those with 4 alterations. CONCLUSIONS AND RELEVANCE: Patient outcomes are associated with alterations of the 4 main driver genes in resected pancreatic adenocarcinoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This is consistent with a previous study of 356 patients with resected PDAC, which reported that those with KRAS mutations had worse disease-free survival (DFS) (median 12.3 months) and OS (median 20.3 months) compared with those with wildtype KRAS (DFS 16.2 months and OS 38.6 months), and particularly poor outcomes were observed in patients with KRASG12D mutation (median OS 15.3 months)39.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [39]
In the citing paper
“Patients with resected PDAC and somatic CDKN2A loss had worse survival (median DFS 11.5 and OS 19.7) compared to patients with wildtype CDKN2A (median DFS 14.8 and median OS 24.6)39.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [39]
In the citing paper
“SMAD4 is a tumor suppressor gene, and reported results about the prognostic value of SMAD4 have been inconsistent39,60–62.”
From Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma (2024) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Genomic analyses identify molecular subtypes of pancreatic cancer
Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621
Self-citationOettle, H., Post, S., Neuhaus, P., Gellert, K., Langrehr, J. M., Ridwelski, K., Schramm, H., Fahlke, J., Zuelke, C., Burkart, C., et al. (2007) · JAMA · doi:10.1001/jama.297.3.267 · Cited by 2,418 · cited 1×
“Furthermore, increasingnumbersofpatientsare receivingchemotherapy and radiation before surgical resection to rapidly initiate therapyagainstmicrometastaticdisease andselect out those patientswith early disease progression unlikely to benefit fromsurgery.(14) In the future,molecular assessmentofpancreatic cancermayhelp…”
BackgroundWhole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115
Iacobuzio-Donahue, C. A., Fu, B., Yachida, S., Luo, M., Abe, H., Henderson, C. M., Vilardell, F., Wang, Z., Keller, J. W., Banerjee, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7188 · Cited by 1,081
SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer
Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Eshleman, J. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0227 · Cited by 371
Yachida, S., White, C. M., Naito, Y., Zhong, Y., Brosnan, J. A., Macgregor-Das, A. M., Morgan, R. A., Saunders, T., Laheru, D. A., Herman, J. M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1215 · Cited by 280
Oshima, M., Okano, K., Muraki, S., Haba, R., Maeba, T., Suzuki, Y., & Yachida, S. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182827a65 · Cited by 236
Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival
Rachakonda, P. S., Bauer, A. S., Xie, H., Campa, D., Rizzato, C., Canzian, F., Beghelli, S., Greenhalf, W., Costello, E., Schanne, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060870 · Cited by 93
Cited by
Sorted by citations
Items 201–264 of 264
Progress in transformation and application of pancreatic lesions
Zhu, J., & Zhang, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819402-7.00007-3
Connor, A. A., Denroche, R. E., Jang, G. H., Lemire, M., Zhang, A. X. W., Chan‐Seng‐Yue, M., Wilson, G. W., Merico, D., Lungu, I. M., Bartlett, J. M. S., et al. (2018) · SSRN Electronic Journal · doi:10.2139/ssrn.3188387
Buscail, L., Bournet, B., Carrère, N., Muscari, F., & Otal, P. (2021) · Elsevier eBooks · doi:10.1016/b978-2-294-77623-6.00006-7
Risk Factors for Pancreatic Cancer and Cholangiocarcinoma
Hamada, T., & Nakai, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-2870-2_1
Ductal Adenocarcinoma and Variants
Karamitopoulou, E. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_5538-1
Shui, L., Li, X., Yang, P., Tian, J., Li, S., He, D., Li, A., Tian, B., Mao, L., Yi, C., et al. (2020) · doi:10.21203/rs.3.rs-60530/v1
Masugi, Y., Takamatsu, M., Tanaka, M. H., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4197932
Self-citationRecommendation: Treatment of pancreatic cancer in 2022 — R1/PR8
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr8
Decision: Treatment of pancreatic cancer in 2022 — R1/PR9
(2023) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr9
Review: Treatment of pancreatic cancer in 2022 — R1/PR7
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr7
Author comment: Treatment of pancreatic cancer in 2022 — R1/PR6
Casolino, R. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr6
Decision: Treatment of pancreatic cancer in 2022 — R0/PR5
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr5
Recommendation: Treatment of pancreatic cancer in 2022 — R0/PR4
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr4
Review: Treatment of pancreatic cancer in 2022 — R0/PR2
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr2
Review: Treatment of pancreatic cancer in 2022 — R0/PR3
(2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr3
Author comment: Treatment of pancreatic cancer in 2022 — R0/PR1
Casolino, R. (2022) · Cambridge Prisms Precision Medicine · doi:10.1017/pcm.2023.2.pr1
Williams, H. L., Costa, A. D., Zhang, J., Raghavan, S., Winter, P. S., Kapner, K. S., Ginebaugh, S. P., Väyrynen, S. A., Väyrynen, J. P., Yuan, C., et al. (2023) · doi:10.1158/0008-5472.c.6514341.v1
Self-citationWilliams, H. L., Costa, A. D., Zhang, J., Raghavan, S., Winter, P. S., Kapner, K. S., Ginebaugh, S. P., Väyrynen, S. A., Väyrynen, J. P., Yuan, C., et al. (2023) · doi:10.1158/0008-5472.c.6514341
Self-citationVäyrynen, S. A., Zhang, J., Yuan, C., Väyrynen, J. P., Costa, A. D., Williams, H. L., Morales-Oyarvide, V., Lau, M. C., Rubinson, D. A., Dunne, R. F., et al. (2023) · doi:10.1158/1078-0432.c.6530165
Self-citationVäyrynen, S. A., Zhang, J., Yuan, C., Väyrynen, J. P., Costa, A. D., Williams, H. L., Morales-Oyarvide, V., Lau, M. C., Rubinson, D. A., Dunne, R. F., et al. (2023) · doi:10.1158/1078-0432.c.6530165.v1
Self-citationLiudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W. E., et al. (2023) · doi:10.1158/2159-8290.22539349
Self-citationLiudahl, S. M., Betts, C. B., Sivagnanam, S., Morales-Oyarvide, V., da Silva, A., Yuan, C., Hwang, S., Grossblatt-Wait, A., Leis, K. R., Larson, W. E., et al. (2023) · doi:10.1158/2159-8290.22539349.v1
Self-citationPersonalized therapy in pancreatic cancer
Liberko, M., & Soumarová, R. (2023) · Onkologie · doi:10.36290/xon.2023.020
Integrated In Silico Analysis of Proteogenomic and Drug Targets for Pancreatic Cancer Survival
Bera, A., Chatterjee, D., Hester, J., & Srivastava, M. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3163-8_19
Zou, S., Wang, X., Chen, H., Lin, J., Wen, C., Zhan, Q., Chen, H., Lu, X., Deng, X., & Shen, B. (2022) · Figshare · doi:10.6084/m9.figshare.20064361
Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., Cheng, D., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24709035
Advances in the Treatment of Unresectable Pancreatic Cancer
薛, 星. (2024) · Journal of Clinical Personalized Medicine · doi:10.12677/jcpm.2024.32079
Kawabata, H., Yuzawa, S., Takahashi, K., Tanino, M. A., & Mizukami, Y. (2024) · Suizo · doi:10.2958/suizo.39.316
Targeted Therapy for Pancreatic Cancer: Focus on KRAS
Keum, J., & Lee, S. H. (2025) · Journal of Digestive Cancer Research · doi:10.52927/jdcr.2025.13.1.52
Studies on geraniol derivatives targeting KRASG12D gene of pancreatic ductal adenocarcinoma
Keerthi, V., Naguraj, T. A., Sudharsan, M. S., & Pazhamalai, V. (2025) · Medicinal Plants - International Journal of Phytomedicines and Related Industries · doi:10.5958/0975-6892.2025.00038.7
Speridonova, A. D., Zaripova, A. R., Gilyazova, I. R., & Bermisheva, M. (2025) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2025-24-3-149-161
Duan, A., Liu, X., Zhao, J., Guo, Y., Zhou, H., Wang, Y., Li, R., & Kang, W. (2025) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-24-2046
Liu, L., Zhu, X., Guo, Y., Tang, M., Zhou, W., & Chen, B. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1687796
Zou, S., Wen, C., Li, F., Jiang, L., Tian, Q., Chen, H. Y., Deng, X., Peng, C., Shen, B., & Zhan, Q. (2025) · Pancreas · doi:10.1097/mpa.0000000000002511
Shui, L., Li, X., Peng, Y., Tian, J., Li, S., He, D., Li, A., Tian, B., Li, M., Gao, H., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14956007
Zou, S., Wang, X., Chen, H., Lin, J., Wen, C., Zhan, Q., Chen, H., Lu, X., Deng, X., & Shen, B. (2022) · Figshare · doi:10.6084/m9.figshare.20064358
Ma, Z., Li, Z., Wang, S., Zhou, Z., Liu, C., Zhuang, H., Zhou, Q., Huang, S., Zhang, C., & 侯宝华 (2022) · Figshare · doi:10.6084/m9.figshare.19549527
Ma, Z., Li, Z., Wang, S., Zhou, Z., Liu, C., Zhuang, H., Zhou, Q., Huang, S., Zhang, C., & 侯宝华 (2022) · Figshare · doi:10.6084/m9.figshare.19549518
Ma, Z., Li, Z., Wang, S., Zhou, Z., Liu, C., Zhuang, H., Zhou, Q., Huang, S., Zhang, C., & 侯宝华 (2022) · Figshare · doi:10.6084/m9.figshare.19549530
Zou, S., Wang, X., Chen, H., Lin, J., Wen, C., Zhan, Q., Chen, H., Lu, X., Deng, X., & Shen, B. (2022) · Figshare · doi:10.6084/m9.figshare.20064355
Ma, Z., Li, Z., Wang, S., Zhou, Z., Liu, C., Zhuang, H., Zhou, Q., Huang, S., Zhang, C., & 侯宝华 (2022) · Figshare · doi:10.6084/m9.figshare.19549524
Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.26648022
Ma, Z., Li, Z., Wang, S., Zhou, Z., Liu, C., Zhuang, H., Zhou, Q., Huang, S., Zhang, C., & 侯宝华 (2022) · Figshare · doi:10.6084/m9.figshare.19549509
Ma, Z., Li, Z., Wang, S., Zhou, Z., Liu, C., Zhuang, H., Zhou, Q., Huang, S., Zhang, C., & 侯宝华 (2022) · Figshare · doi:10.6084/m9.figshare.19549512
Yun, W.-G., Kim, D., Lee, M., Han, Y., Chae, Y. S., Jung, H.-S., Cho, Y. J., Kwon, W., Park, J. S., Park, D., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26839044
Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.24709141
Ma, Z., Li, Z., Wang, S., Zhou, Z., Liu, C., Zhuang, H., Zhou, Q., Huang, S., Zhang, C., & 侯宝华 (2022) · Figshare · doi:10.6084/m9.figshare.19549515
Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.26648016
Zhou, Y., Jin, J., Ji, Y., Zhang, J., Fu, N., Chen, M., Wang, J., Qin, K., Jiang, Y., 程东峰, et al. (2024) · Figshare · doi:10.6084/m9.figshare.26648019
Utility of genome profiling and liquid biopsy in the new era of pancreatic cancer precision medicine
Okada, T., Itoh, T., ISHII, T., Yusuke, O. N. O., TAKAHASHI, K., & Mizukami, Y. O. (2025) · Suizo · doi:10.2958/suizo.40.130
Hayasaki, A., Nagata, M., Usui, M., Imai, H., Iizawa, Y., Tanemura, A., Murata, Y., Kuriyama, N., Kishiwada, M., & MIZUNO, S. (2026) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.70186
Co-targeting an AMPK–MAPK axis reprograms fibroblasts and suppresses PDACPreprint
Yamamura, R., Satoh, Y., Fukuda, J., Kimura, T., Otsuka, T., Sekiya, S., Hirata, T., Hata, S., Sato, R., Kamijo, C., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.16.711738
Characterisation of SG33 Myxoma virus replication and oncolytic activity in pancreatic cancer models
Quillien, L. (2021) · theses.fr (ABES) · doi:10.70675/eadfa28azee41z4b56z88f3zc40b7ff9f900
Amal, A. M., Ahmed, M. S. M., Hareedy, A. A., Khattab, H., & Mahmoud, E. K. (2026) · Journal of Microscopy and Ultrastructure · doi:10.4103/jmau.jmau_71_23 · Cited by 1
Wang, R., Liu, S., Ding, J., Sun, Y., Zhou, J., Peng, B., & Wu, Z. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01408-x
Varzaru, B., Croitoru, A. E., Sorop, A., Lupescu, I. G., Dima, S., Iacob, R. A., Becheanu, G., & Gheorghe, C. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9030285
“The co-occurrence of KRAS and SMAD4 mutations defines a high-risk molecular subtype, commonly associated with poor prognosis, enhanced metastatic potential, and limited responsiveness to standard chemotherapy [7,8,12–15].”
Hai, H., Ooshio, T., Jiang, H., Kimura, T., Satoh, Y., Hata, S., Hirata, T., Liu, J., Liu, T., Yamamura, R., et al. (2026) · Cancer Science · doi:10.1111/cas.70522
“These findings indicate that the accumulation of core PDAC driver alterations drives graded epithelial disruption in Drosophila , consistent with clinical correlations between increasing driver burden and poor outcomes [9, 33].”
ARNTL2 promotes metastatic phenotypes through SERPINE1 transcription in KRAS G12D pancreatic cancer
Shi, X., Yin, X., Gao, S., Wu, X., Wang, H., Wang, B., Xu, X., Zheng, K., Wei, J., Li, G., et al. (2026) · iScience · doi:10.1016/j.isci.2026.117479
“26 Congruent with prior clinical data indicating KRAS G12D as the poorest prognostic subtype among KRAS alleles, 7,8 our TCGA mining revealed KRAS G12D as the predominant subtype, within which ARNTL2 exhibited significant upregulation.”
Integrated driver gene-based survival prediction in resected pancreatic cancer
Li, Z., Campbell, B. A., Molin, M. D., Song, Y., McPhaul, T. J., Zhang, S., Cameron, J. L., Lin, M.-T., Hruban, R. H., Shubert, C. R., et al. (2026) · British journal of surgery · doi:10.1093/bjs/znag123
Williams, T. M., Moughan, J., Regine, W. F., Timmers, C. D., Robb, R. N., Cui, T., DiPetrillo, T. A., Leasure, N. C., Kim, H., Doncals, D. E., et al. (2026) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2026.09.014
Ali, M. M., Aragon, K. K., Cher, B. A. Y., Ahmed, K. S., Marcinak, C. T., Acher, A. W., Kratz, J., Murtaza, M., Burkard, M. E., & Zafar, S. N. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04564-6
Metadata
- Authors
- Qian, Z. R., Rubinson, D. A., Nowak, J. A., Morales-Oyarvide, V., Dunne, R. F., Kozak, M. M., Welch, M. W., Brais, L. K., Da Silva, A., Li, T., Li, W., Masuda, A., Yang, J., Shi, Y., Gu, M., Masugi, Y., Bui, J., Zellers, C. L., Yuan, C., Babic, A., Khalaf, N., Aguirre, A., Ng, K., Miksad, R. A., Bullock, A. J., Chang, D. T., Tseng, J. F., Clancy, T. E., Linehan, D. C., Findeis-Hosey, J. J., Doyle, L. A., Thorner, A. R., Ducar, M., Wollison, B., Laing, A., Hahn, W. C., Meyerson, M., Fuchs, C. S., Ogino, S., Hornick, J. L., Hezel, A. F., Koong, A. C., & Wolpin, B. M.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts
- University of Rochester Medicine (US)
- Stanford Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Broad Institute (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Wolpin, Brian M.
- ORCID
- Qian, Zhi Rong
- Rubinson, Douglas A.
- Nowak, Jonathan A.
- Dunne, Richard F.
- Kozak, Margaret M.
- Brais, Lauren K.
- Li, Tingting
- Li, Wanwan
- Masuda, Atsuhiro
- Yang, Juhong
- Shi, Yan
- Gu, Mancang
- Masugi, Yohei
- Bui, Justin
- Yuan, Chen
- Khalaf, Natalia
- Aguirre, Andrew
- Ng, Kimmie
- Miksad, Rebecca A.
- Bullock, Andrea J.
- Chang, Daniel T.
- Tseng, Jennifer F.
- Clancy, Thomas E.
- Linehan, David C.
- Findeis-Hosey, Jennifer J.
- Doyle, Leona A.
- Thorner, Aaron R.
- Ducar, Matthew
- Wollison, Bruce
- Hahn, William C.
- Meyerson, Matthew
- Fuchs, Charles S.
- Ogino, Shuji
- Hornick, Jason L.
- Hezel, Aram F.
- Koong, Albert C.
- Wolpin, Brian M.
- Venue
- JAMA Oncology
- Publisher
- American Medical Association (AMA)
- Published
- 2018-03-08
- Volume
- 4
- Issue
- 3
- Pages
- e173420
- ISSN
- 2374-2437 (ISSN-L)
- PMC
- PMC5844844
- OpenAlex
- W2767007332
- Cited by
- 260
- References
- 15
- Citations by year
- 2026: 17 · 2025: 31 · 2024: 38 · 2023: 47 · 2022: 49 · 2021: 28 · 2020: 24 · 2019: 19 · 2018: 7
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- JAMA Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pancreatic Cancer Action Network
- National Institutes of Health (UL1TR001102, UL1TR001863)
- National Cancer Institute (P50CA127003, R01CA124908, R35CA197735, K07CA148894, U01CA176058, U01CA199253, K08CA218420, U01CA210171)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Surgery › Cholangiocarcinoma and Gallbladder Cancer Studies
- Keywords
- pancreatic ductal adenocarcinoma, pancreatic cancer surgery, driver gene alterations, KRAS mutation, CDKN2A, SMAD4, TP53, disease-free survival, overall survival, prognostic factors, protein expression, DNA alterations, recurrence, postoperative adjuvant therapy, neoadjuvant therapy, tumor-infiltrating lymphocytes, tumor-infiltrating macrophages, tumor-infiltrating neutrophils, tumor-infiltrating T cells, tumor-infiltrating B cells, tumor-infiltrating plasma cells, tumor-infiltrating dendritic cells, tumor-infiltrating NK cells, tumor-infiltrating Treg cells, tumor-infiltrating myeloid cells
- MeSH terms
- Adenocarcinoma, Aged, DNA Mutational Analysis, Female, Follow-Up Studies, Humans, Immunohistochemistry, Male, Middle Aged, Mutation, Pancreatectomy, Pancreatic Neoplasms, Prognosis, Proto-Oncogene Proteins, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Survival Analysis, Treatment Outcome, Gene Expression Profiling, Carcinoma, Pancreatic Ductal, High-Throughput Nucleotide Sequencing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
